SMA1
MCID: SPN393
MIFTS: 50

Spinal Muscular Atrophy, Type I (SMA1)

Categories: Genetic diseases, Muscle diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Spinal Muscular Atrophy, Type I

MalaCards integrated aliases for Spinal Muscular Atrophy, Type I:

Name: Spinal Muscular Atrophy, Type I 57
Werdnig-Hoffmann Disease 57 12 73 20 58 29 54 6 15
Sma1 57 12 20 58 72
Spinal Muscular Atrophy 1 12 20 72
Proximal Spinal Muscular Atrophy Type 1 20 58
Muscular Atrophy, Infantile 57 20
Infantile Muscular Atrophy 12 72
Sma, Infantile Acute Form 57 20
Spinal Muscular Atrophy-1 57 13
Hmn Proximal Type I 12 70
Sma Type 1 20 58
Sma Type I 20 58
Sma I 57 72
Sma-I 20 58
Hereditary Motor Neuropathy Proximal Type I 12
Proximal Hereditary Motor Neuropathy Type I 72
Proximal Spinal Muscular Atrophy, Type 1 20
Progressive Muscular Atrophy of Infancy 12
Infantile Spinal Muscular Atrophy 58
Atrophy, Muscular, Spinal, Type 1 39
Spinal Muscular Atrophy Type I 72
Werdnig Hoffmann Disease 20
Sma Infantile Acute Form 72
Werdnig-Hoffman Disease 72

Characteristics:

Orphanet epidemiological data:

58
proximal spinal muscular atrophy type 1
Inheritance: Autosomal recessive; Age of onset: Infancy,Neonatal;

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
autosomal recessive

Miscellaneous:
death secondary to respiratory infection or failure before age 2 years
onset birth to 6 months
incidence 1 in 6,000 to 1 in 8,000 live births
approximately 45% of sma1 patients also are missing both homologs of neuronal apoptosis inhibitory protein (naip, ), which may play a role in modifying disease severity
exon 7 of smn1 is absent in 95.6% of sma1 patients


HPO:

31
spinal muscular atrophy, type i:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:13137
OMIM® 57 253300
ICD9CM 34 335.0
MeSH 44 D014897
NCIt 50 C98670
SNOMED-CT 67 64383006
ICD10 32 G12.0
ICD10 via Orphanet 33 G12.0
UMLS via Orphanet 71 C0043116
Orphanet 58 ORPHA83330
MedGen 41 C0043116
UMLS 70 C0043116

Summaries for Spinal Muscular Atrophy, Type I

GARD : 20 Spinal muscular atrophy 1 (SMA1), also known as Werdnig Hoffmann disease, is a genetic neuromuscular disorder that affects the nerve cells that control voluntary muscles (motor neurons). Without treatment, symptoms of SMA1 become apparent before 6 months of age and include worsening muscle weakness and poor muscle tone ( hypotonia ) due to loss of the lower motor neurons in the spinal cord and brain stem. Feeding and breathing problems are also present. SMA1 is caused by changes (pathogenic variants also called mutations ) in the SMN1 gene and is typically inherited in an autosomal recessive manner. Diagnosis of SMA1 is suspected by symptoms and confirmed by genetic testing. SMA has been added to the list of recommended newborn screening tests in the United States, so that it can be detected prior to symptoms developing. This occurred because treatments are being developed that are changing the course of the disease. In December 2016, nusinersen (Spinraza) became the first FDA approved treatment for SMA1. Continued treatment with nusinersen is allowing many babies with SMA1 to reach and maintain age appropriate developmental milestones, including sitting, crawling, and walking. On average, breathing problems, nutrition problems, and hospital admissions have also decreased. However, response to treatment does vary. Some babies with SMA1 may not respond to the nusinersen at all or may have medical complications that prevent use of the treatment. Other treatments remain supportive.

MalaCards based summary : Spinal Muscular Atrophy, Type I, also known as werdnig-hoffmann disease, is related to spinal muscular atrophy, x-linked 2 and spinal muscular atrophy. An important gene associated with Spinal Muscular Atrophy, Type I is SMN1 (Survival Of Motor Neuron 1, Telomeric). The drugs Valproic acid and Psychotropic Drugs have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, tongue and heart, and related phenotypes are respiratory insufficiency and recurrent respiratory infections

Disease Ontology : 12 A childhood spinal muscular atrophy that is a severe form and is characterized by muscle weakness onset from birth to six months of age, the inability to sit unassisted.

OMIM® : 57 Spinal muscular atrophy refers to a group of autosomal recessive neuromuscular disorders characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy (summary by Wirth, 2000). Four types of SMA are recognized depending on the age of onset, the maximum muscular activity achieved, and survivorship: type I, severe infantile acute SMA, or Werdnig-Hoffman disease; type II (253550), or infantile chronic SMA; type III (253400), juvenile SMA, or Wohlfart-Kugelberg-Welander disease; and type IV (271150), or adult-onset SMA. All types are caused by recessive mutations in the SMN1 gene. Lunn and Wang (2008) provided a detailed review of clinical features, molecular pathogenesis, and therapeutic strategies for SMA. (253300) (Updated 20-May-2021)

UniProtKB/Swiss-Prot : 72 Spinal muscular atrophy 1: A form of spinal muscular atrophy, a group of neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Autosomal recessive forms are classified according to the age of onset, the maximum muscular activity achieved, and survivorship. The severity of the disease is mainly determined by the copy number of SMN2, a copy gene which predominantly produces exon 7-skipped transcripts and only low amount of full-length transcripts that encode for a protein identical to SMN1. Only about 4% of SMA patients bear one SMN1 copy with an intragenic mutation. SMA1 is a severe form, with onset before 6 months of age. SMA1 patients never achieve the ability to sit.

Wikipedia : 73 Spinal muscular atrophy (SMA) is a rare neuromuscular disorder that results in the loss of motor neurons... more...

Related Diseases for Spinal Muscular Atrophy, Type I

Diseases in the Spinal Muscular Atrophy family:

Spinal Muscular Atrophy, Type I Spinal Muscular Atrophy, Type Iii
Spinal Muscular Atrophy, Type Ii Spinal Muscular Atrophy, Type Iv
Spinal Muscular Atrophy Type 0 Congenital Benign Spinal Muscular Atrophy Dominant

Diseases related to Spinal Muscular Atrophy, Type I via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 138)
# Related Disease Score Top Affiliating Genes
1 spinal muscular atrophy, x-linked 2 32.8 SMN2 SMN1 IGHMBP2
2 spinal muscular atrophy 32.7 SMN2 SMN1 SCO2 NAIP IGHMBP2 GTF2H2
3 mitochondrial complex iv deficiency, nuclear type 2 32.1 SCO2 NCAPH2
4 spinal muscular atrophy, type iii 32.0 UNC119 SMN2 SMN1 NAIP IGHMBP2 GTF2H2
5 muscular atrophy 31.8 SMN2 SMN1 SCO2 NAIP IGHMBP2 GTF2H2
6 proximal spinal muscular atrophy 31.3 SMN2 SMN1 NAIP
7 motor neuron disease 31.2 SYP SMN2 SMN1 NAIP
8 neuromuscular disease 31.2 SMN2 SMN1 NAIP IGHMBP2
9 amyotrophic lateral sclerosis 1 31.1 SYP SMN2 SMN1 SACM1L NAIP IGHMBP2
10 myopia 6 30.8 SCO2 NCAPH2
11 cardioencephalomyopathy 30.8 SCO2 NCAPH2
12 anterior horn cell disease 30.7 SMN2 SMN1 IGHMBP2
13 spinal muscular atrophy, distal, autosomal recessive, 1 30.7 SMN2 SMN1 IGHMBP2
14 neuronopathy, distal hereditary motor, type va 30.6 SMN2 SMN1 IGHMBP2
15 progressive muscular atrophy 30.4 SMN2 SMN1
16 spinal muscular atrophy, type ii 30.2 UNC119 SMN2 SMN1 NAIP INE2 IGHMBP2
17 childhood spinal muscular atrophy 29.2 WASH2P UNC119 TMEM47 ST8SIA4 SMN2 SMN1
18 spinal muscular atrophy with congenital bone fractures 1 11.5
19 pontocerebellar hypoplasia, type 1e 11.3
20 spinal muscular atrophy, lower extremity-predominant, 1, autosomal dominant 10.9
21 spinal and bulbar muscular atrophy, x-linked 1 10.9
22 pontocerebellar hypoplasia, type 1a 10.9
23 spinal muscular atrophy, infantile, james type 10.9
24 lateral sclerosis 10.6
25 myopathy 10.5
26 hypotonia 10.4
27 spinal muscular atrophy type 0 10.4 SMN2 SMN1
28 nephrolithiasis/osteoporosis, hypophosphatemic, 2 10.4 SMN2 SMN1
29 autosomal recessive distal hereditary motor neuronopathy 10.4 SMN2 SMN1 IGHMBP2
30 chronic inflammatory demyelinating polyneuritis 10.4 SMN2 SMN1
31 spinal muscular atrophy, type iv 10.4 SMN2 SMN1 NAIP
32 congenital contractures 10.3
33 spinal muscular atrophy, distal, autosomal recessive, 4 10.3 SMN2 SMN1
34 mitochondrial dna depletion syndrome 1 10.3 SCO2 NCAPH2
35 spinal disease 10.3 SMN2 SMN1 NAIP
36 spherocytosis, type 1 10.3 ST8SIA4 SFI1 SACM1L CNOT1
37 dubowitz syndrome 10.3 SMN2 SMN1
38 hereditary neuropathies 10.3
39 amyotonia congenita 10.3
40 batten-turner congenital myopathy 10.3
41 distal arthrogryposis 10.3
42 cerebellar hypoplasia 10.3
43 peripheral nervous system disease 10.3
44 wallerian degeneration 10.3
45 congenital amyoplasia 10.3
46 spinal muscular atrophy with progressive myoclonic epilepsy 10.3 SMN2 SMN1
47 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
48 aspiration pneumonia 10.2
49 autosomal recessive disease 10.2
50 respiratory failure 10.2

Graphical network of the top 20 diseases related to Spinal Muscular Atrophy, Type I:



Diseases related to Spinal Muscular Atrophy, Type I

Symptoms & Phenotypes for Spinal Muscular Atrophy, Type I

Human phenotypes related to Spinal Muscular Atrophy, Type I:

31 (show all 12)
# Description HPO Frequency HPO Source Accession
1 respiratory insufficiency 31 HP:0002093
2 recurrent respiratory infections 31 HP:0002205
3 atrial septal defect 31 HP:0001631
4 proximal muscle weakness in lower limbs 31 HP:0008994
5 areflexia 31 HP:0001284
6 ventricular septal defect 31 HP:0001629
7 decreased fetal movement 31 HP:0001558
8 respiratory failure 31 HP:0002878
9 proximal amyotrophy 31 HP:0007126
10 emg: neuropathic changes 31 HP:0003445
11 tongue fasciculations 31 HP:0001308
12 spinal muscular atrophy 31 HP:0007269

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Cardiovascular Heart:
atrial septal defect
ventricular septal defect
congenital cardiac malformations have been rarely reported in severe cases

Prenatal Manifestations Movement:
decreased fetal movement

Neurologic Central Nervous System:
areflexia
muscle atrophy
emg shows neurogenic abnormalities
muscle weakness, symmetric, proximal (lower limbs more affected than upper limbs) due to motor neuronopathy
affected children are unable to sit without support
more
Respiratory:
respiratory failure

Clinical features from OMIM®:

253300 (Updated 20-May-2021)

Drugs & Therapeutics for Spinal Muscular Atrophy, Type I

Drugs for Spinal Muscular Atrophy, Type I (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 6)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic acid Approved, Investigational Phase 1, Phase 2 99-66-1 3121
2 Psychotropic Drugs Phase 1, Phase 2
3 Neurotransmitter Agents Phase 1, Phase 2
4 carnitine Phase 1, Phase 2
5 Anticonvulsants Phase 1, Phase 2
6 4-phenylbutyric acid Phase 1, Phase 2

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101 Enrolling by invitation NCT04042025 Phase 4
2 Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion Active, not recruiting NCT03837184 Phase 3
3 The Effectiveness of Allogeneic Adipose Derived Mesenchymal Stem Cells (ADMSCs) in the Phenotypic Changes of Werdnig Hoffman Patients Unknown status NCT02855112 Phase 1, Phase 2
4 Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I) Completed NCT00661453 Phase 1, Phase 2 Valproic Acid and Levocarnitine
5 Phase I/IIa Clinical Trial of Sodium Phenylbutyrate in Pediatric Subjects With Type I Spinal Muscular Atrophy Terminated NCT00439218 Phase 1, Phase 2 sodium phenylbutyrate
6 Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101 Completed NCT02122952 Phase 1
7 Evaluation of Palliative and Supportive Care for Spinal Muscular Atrophy (SMA) Type 1 Patients Completed NCT01862042
8 The Burden of Primary Caregivers of Spinal Muscular Atrophy Patients and Their Needs Completed NCT04228718
9 Controlled Trial Evaluating the Interest of Noninvasive Ventilation in NAVA Mode in Respiratory Decompensations Children With Infantile Spinal Muscular Atrophy Type II Recruiting NCT03395795
10 A Long Term Follow up Safety Study of Patients in the AVXS-101-CL-101 Gene Replacement Therapy Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS 101 Active, not recruiting NCT03421977
11 Physical Exercise and Neuromuscular Diseases: Pilot Study of an Innovative Physiotherapy in Patients With Infantile Spinal Muscular Atrophy Active, not recruiting NCT02061189
12 A Pilot Study of the Natural History of Infants With Spinal Muscular Atrophy (SMA) Type 1 Terminated NCT01547871

Search NIH Clinical Center for Spinal Muscular Atrophy, Type I

Genetic Tests for Spinal Muscular Atrophy, Type I

Genetic tests related to Spinal Muscular Atrophy, Type I:

# Genetic test Affiliating Genes
1 Werdnig-Hoffmann Disease 29 SMN1

Anatomical Context for Spinal Muscular Atrophy, Type I

MalaCards organs/tissues related to Spinal Muscular Atrophy, Type I:

40
Spinal Cord, Tongue, Heart, Skeletal Muscle, Bone, Cerebellum, Brain

Publications for Spinal Muscular Atrophy, Type I

Articles related to Spinal Muscular Atrophy, Type I:

(show top 50) (show all 426)
# Title Authors PMID Year
1
Identification and characterization of a spinal muscular atrophy-determining gene. 57 6
7813012 1995
2
Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling. 57 54
19780763 2009
3
Werdnig-Hoffmann disease: report of the first case clinically identified and genetically confirmed in central Africa (Kinshasa-Congo). 57 61
20162870 2009
4
Congenital heart disease is a feature of severe infantile spinal muscular atrophy. 54 57
18662980 2008
5
Evidence of reduced frequency of spinal muscular atrophy type I in the Cuban population. 61 57
16116135 2005
6
An 11 base pair duplication in exon 6 of the SMN gene produces a type I spinal muscular atrophy (SMA) phenotype: further evidence for SMN as the primary SMA-determining gene. 6 54
8922999 1996
7
Large scale deletions of the 5q13 region are specific to Werdnig-Hoffmann disease. 61 57
8730281 1996
8
The natural history of type I (severe) spinal muscular atrophy. 61 57
7881295 1994
9
Prenatal prediction of Werdnig-Hoffmann disease using linked polymorphic DNA probes. 57 61
1348092 1992
10
Prevalence of type I spinal muscular atrophy in North Dakota. 57 61
1785637 1991
11
A hungarian study on Werdnig-Hoffmann disease. 57 61
2614795 1989
12
Cluster of acute infantile spinal muscular atrophy (Werdnig-Hoffmann disease) in a limited area of Reunion Island. 57 61
6467653 1984
13
Werdnig-Hoffmann disease. The effects of intrauterine onset on lung growth. 61 57
747396 1978
14
High incidence of spinal muscular atrophy type I (Werdnig - Hoffmann disease) in the Karaite community in Israel. 61 57
912942 1977
15
SMN regulates axonal local translation via miR-183/mTOR pathway. 57
25055867 2014
16
Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. 57
25104390 2014
17
Plastin 3 ameliorates spinal muscular atrophy via delayed axon pruning and improves neuromuscular junction functionality. 57
23263861 2013
18
An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. 57
22975760 2013
19
A novel function for the survival motoneuron protein as a translational regulator. 6
23136128 2013
20
A common spinal muscular atrophy deletion mutation is present on a single founder haplotype in the US Hutterites. 57
21610747 2011
21
SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. 57
20705736 2010
22
Association of plastin 3 expression with disease severity in spinal muscular atrophy only in postpubertal females. 57
20937953 2010
23
Molecular characterization of SMN copy number derived from carrier screening and from core families with SMA in a Chinese population. 57
20442745 2010
24
Stathmin, a microtubule-destabilizing protein, is dysregulated in spinal muscular atrophy. 57
20176735 2010
25
Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. 57
20097679 2010
26
Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. 57
19897588 2010
27
Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophy. 57
19884170 2010
28
Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. 57
19625298 2009
29
Differences in SMN1 allele frequencies among ethnic groups within North America. 57
19625283 2009
30
A SMN missense mutation complements SMN2 restoring snRNPs and rescuing SMA mice. 57
19329542 2009
31
Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation. 57
19010792 2009
32
Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene. 57
19050931 2009
33
Induced pluripotent stem cells from a spinal muscular atrophy patient. 57
19098894 2009
34
Carrier frequency of spinal muscular atrophy. 57
18984183 2008
35
Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. 57
18661558 2008
36
Unaffected patients with a homozygous absence of the SMN1 gene. 57
18337729 2008
37
Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. 57
18492800 2008
38
Spinal muscular atrophy. 57
18572081 2008
39
Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. 57
18440926 2008
40
Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect. 57
18178576 2008
41
5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells. 57
17924536 2008
42
Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. 57
17932121 2008
43
The changing natural history of spinal muscular atrophy type 1. 57
17998484 2007
44
Stat5 constitutive activation rescues defects in spinal muscular atrophy. 57
17220171 2007
45
In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. 57
16607616 2006
46
Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. 57
16049920 2005
47
Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy. 6
15580564 2005
48
Detection of novel mutations in the SMN Tudor domain in type I SMA patients. 6
15249625 2004
49
Spinal muscular atrophy: molecular genetics and diagnostics. 57
14711346 2004
50
Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. 57
14560316 2004

Variations for Spinal Muscular Atrophy, Type I

ClinVar genetic disease variations for Spinal Muscular Atrophy, Type I:

6 (show all 19)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SMN1 NM_001297715.1(SMN1):c.835-497G>T SNV Pathogenic 9167 rs76163360 GRCh37: 5:70247769-70247769
GRCh38: 5:70951942-70951942
2 SMN1 SMN1, 5-BP DEL, 425 Deletion Pathogenic 9171 GRCh37:
GRCh38:
3 SMN1 NM_000344.3(SMN1):c.346A>T (p.Ile116Phe) SNV Pathogenic 9179 rs104893933 GRCh37: 5:70238257-70238257
GRCh38: 5:70942430-70942430
4 SMN1 NM_000344.3(SMN1):c.406C>G (p.Gln136Glu) SNV Pathogenic 9180 rs104893934 GRCh37: 5:70238317-70238317
GRCh38: 5:70942490-70942490
5 SMN1 NM_000344.3(SMN1):c.770_780dup (p.Gly261fs) Duplication Pathogenic 586627 rs1561500847 GRCh37: 5:70241936-70241937
GRCh38: 5:70946109-70946110
6 SMN1 SMN1, 11-BP DUP, 801-811 Duplication Pathogenic 9163 GRCh37:
GRCh38:
7 SMN1 NC_000005.10:g.70936291_70945268del Deletion Pathogenic 692109 GRCh37:
GRCh38:
8 SMN1 GRCh37/hg19 5q13.2(chr5:70247768-70248841)x1 copy number loss Pathogenic 983311 GRCh37: 5:70247768-70248841
GRCh38:
9 SMN1 GRCh37/hg19 5q13.2(chr5:70247768-70248841)x1 copy number loss Pathogenic 983312 GRCh37: 5:70247768-70248841
GRCh38:
10 SMN1 NM_000344.4(SMN1):c.724_885del (p.Ile242_Ter295del) Deletion Pathogenic 973541 GRCh37: 5:70241893-70247818
GRCh38: 5:70946066-70951991
11 SMN1 NM_022874.2(SMN1):c.397_398AG[1] (p.Glu134fs) Microsatellite Pathogenic 634947 rs77668214 GRCh37: 5:70238308-70238311
GRCh38: 5:70942481-70942484
12 SMN1 NM_000344.3(SMN1):c.332C>G (p.Ala111Gly) SNV Pathogenic 9177 rs104893935 GRCh37: 5:70238243-70238243
GRCh38: 5:70942416-70942416
13 SMN1 Deletion Pathogenic 431179 rs1554082110 GRCh37: 5:70241892-70242002
GRCh38: 5:70946065-70946175
14 SMN1 NM_000344.3(SMN1):c.840C>T (p.Phe280=) SNV Pathogenic 586628 rs1164325688 GRCh37: 5:70247773-70247773
GRCh38: 5:70951946-70951946
15 SMN1 NM_000344.3(SMN1):c.835-2A>G SNV Pathogenic 632985 rs141760116 GRCh37: 5:70247766-70247766
GRCh38: 5:70951939-70951939
16 SMN1 NM_000344.4(SMN1):c.280G>T (p.Val94Phe) SNV Likely pathogenic 929467 GRCh37: 5:70238191-70238191
GRCh38: 5:70942364-70942364
17 SMN1 NM_000344.4(SMN1):c.*3+3A>T SNV Likely pathogenic 929483 GRCh37: 5:70247824-70247824
GRCh38: 5:70951997-70951997
18 SMN1 NM_000344.3(SMN1):c.815A>G (p.Tyr272Cys) SNV Likely pathogenic 9166 rs104893922 GRCh37: 5:70241984-70241984
GRCh38: 5:70946157-70946157
19 SMN1 NM_000344.3(SMN1):c.490C>A (p.Gln164Lys) SNV Uncertain significance 634937 rs1561499713 GRCh37: 5:70238560-70238560
GRCh38: 5:70942733-70942733

UniProtKB/Swiss-Prot genetic disease variations for Spinal Muscular Atrophy, Type I:

72
# Symbol AA change Variation ID SNP ID
1 SMN1 p.Tyr272Cys VAR_005617 rs104893922
2 SMN1 p.Gly279Val VAR_005620 rs76163360
3 SMN1 p.Ile116Phe VAR_034807 rs104893933
4 SMN1 p.Gln136Glu VAR_034808 rs104893934

Expression for Spinal Muscular Atrophy, Type I

Search GEO for disease gene expression data for Spinal Muscular Atrophy, Type I.

Pathways for Spinal Muscular Atrophy, Type I

GO Terms for Spinal Muscular Atrophy, Type I

Cellular components related to Spinal Muscular Atrophy, Type I according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 SMN-Sm protein complex GO:0034719 9.16 SMN2 SMN1
2 Gemini of coiled bodies GO:0097504 8.96 SMN2 SMN1
3 SMN complex GO:0032797 8.62 SMN2 SMN1

Biological processes related to Spinal Muscular Atrophy, Type I according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 9.35 UNC119 ST8SIA4 SMN2 SMN1 NAIP
2 spliceosomal snRNP assembly GO:0000387 9.32 SMN2 SMN1
3 spliceosomal complex assembly GO:0000245 9.26 SMN2 SMN1
4 import into nucleus GO:0051170 9.16 SMN2 SMN1
5 DNA-templated transcription, termination GO:0006353 8.62 SMN2 SMN1

Sources for Spinal Muscular Atrophy, Type I

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....